Browsing by Author "Corzo, A"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Patients Age 40 Years and Younger with Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence from Latin America
    (Lippincott Williams and Wilkins, 2023) Martinez-Cordero, H; Peña, C; Schutz, NP; Bove, V; Villano, F; Beltran, C; Donoso, J; Lopez-Vidal, H; Roa-Salinas, MA; Soto, P; Ochoa, P; Duarte, P; Remaggi, G; Corzo, A; Shanley, C; Lopresti, S; Orlando, S; Verri, V; Quiroga, LD; Fantl, D; Ramirez, J; Ospina-Idarraga, A; Idrobo, H; Quintero, G; Gomez, R; Cantu-Martinez, O; Gomez-Almaguer, D; Ruiz-Arguelles, GJ; Galvez-Cardenas, KM; Salazar, LA; Novoa-Caicedo, I; Fuentes-Lacouture, MC; Spirko, P; Arbelaez, MI; Pereira, M; Valdes, J; Vasquez, J; Von-Glasenapp, A; Riva, E
    PURPOSEMultiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce.PATIENTS AND METHODSWe analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older.RESULTSThere were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Of the patients age 40 years or younger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival.CONCLUSIONIn conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly. © American Society of Clinical Oncology.
  • Thumbnail Image
    Publication
    Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
    (Lippincott Williams and Wilkins, 2022) Riva E; Duarte PJ; Valcárcel, B; Remaggi, G; Murrieta, I; Corzo, A; Del Carpio, D; Peña, C; Vásquez, J; Bove, V; Teixeira, L; Fleury-Perini, G; Yantorno, S; Samánez, C; Lopresti, S; Altamirano, M; Villela, L; Ruiz-Arguelles, GJ; Ruiz-Delgado, GJ; Montaño, E; Verri, V; Zamora-Pérez, E; Pérez-Jacobo, F; Idrobo, H; Martínez-Cordero, H; Beltran, BE; Ramírez, J; Castillo, JJ; Malpica-Castillo, LE
    PURPOSE: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America. METHODS: We retrospectively analyzed patients with WM diagnosed between 1991 and 2019 from 24 centers in seven Latin American countries. The study outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS: We identified 159 cases (median age 67 years, male 62%). Most patients (95%) were symptomatic at diagnosis. The International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients were tested for MYD88L265P, with 89% (n = 24 of 27) carrying the mutation. First-line and second-line therapies were administered to 142 (89%) and 53 (33%) patients, respectively. Chemoimmunotherapy was the most commonly used first-line (66%) and second-line (45%) approach